Leprosy in French Guiana, 2015 to 2021: Dynamics of a Persistent Public Health Problem

A resurgence of leprosy as a public health problem in French Guiana was reported over the period 2007 to 2014, particularly among Brazilians gold miners. Prolonged multidrug therapy and reversal reactions represent a therapeutic challenge. The objective of this study was to assess the evolution of leprosy in this European overseas territory. All patients with leprosy confirmed in histopathology between 1 January 2015 and 31 December 2021 were included. A total of 86 patients were included, including 64 new cases and 22 previously diagnosed cases. Sixty patients (70%) were male, 6 cases were paediatric. Brazilian gold miners represented 44.1% of reported occupations (15/34). Maroons represented the second community (13 patients, 15%). Multibacillary and paucibacillary forms were found in 53 (71%) and 22 (29%) patients, respectively. The annual prevalence never exceeded the threshold of 1/10,000. The mean incidence and prevalence were significantly lower than during the period 2007 to 2014 (p < 0.0001). Reversal reactions were found in 29 patients and almost always required a long course of steroids. Infliximab allowed a reduction in the length of treatment with steroids in 2/2 cases. In conclusion, the prevalence of leprosy has decreased significantly in French Guiana, but remains driven by the population of illegal gold miners. Anti-tumour necrosis factor (anti-TNF) drugs represent a promising option in the management of reversal reactions. SIGNIFICANCE This study recorded 86 patients with leprosy in French Guiana between 2015 and 2021, including 64 new cases. The incidence was significantly lower than during the period 2007 to 2014, suggesting that efforts in detection and treatment were successful. Almost half of these cases were found in illegal Brazilian gold miners work-ing in the forest hinterland. Reversal reactions, immune complications, which lengthen the duration of treatment, were found in 22 patients. In 2 of these patients, a new drug (infliximab) allowed the steroids, which were used to treat the reversal reactions but were associated with side-effects, were stopped.